Education
About Us
Working with TipRanks
Follow Us
Xvivo Perfusion AB (XVIPF)
OTHER OTC:XVIPF
Earnings Data
Report Date
Jan 27, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.07Last Year’s EPS
0.12Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in the Abdominal segment and strategic partnerships for service expansion in the U.S. However, challenges remain with slowed growth in the U.S. lung market and delays in regulatory approvals for heart and liver products.Company Guidance
Abdominal Segment Growth
The Abdominal segment achieved a record quarter with net sales of SEK 55 million and an organic growth of 47%. Liver sales grew by 34% in local currencies, and kidney sales increased by 79% year-over-year.
Strong Thoracic Segment Gross Margin
The Thoracic segment's gross margin was 89%, driven by product mix and a 17% growth in global PERFADEX sales, which is the product with the highest margin.
Successful Partnership for U.S. Service Expansion
XVIVO partnered with a perfusionist company, gaining access to 175 perfusionists to improve EVLP and organ recovery services in the U.S.
Improved Service Model
XVIVO introduced an EVLP product service model to better fit the OPO system, with the first pilot scheduled for Q4.
Positive Cash Flow Management
Operating cash flow was positive at SEK 21 million during Q3, with disciplined cost management offsetting recruitment costs.
XVIPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XVIPF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 23, 2025 | $19.10 | $19.20 | +0.52% |
Jul 11, 2025 | $30.95 | $21.64 | -30.08% |
Apr 24, 2025 | $30.80 | $33.45 | +8.60% |
Jan 28, 2025 | $38.14 | $40.38 | +5.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xvivo Perfusion AB (XVIPF) report earnings?
Xvivo Perfusion AB (XVIPF) is schdueled to report earning on Jan 27, 2026, TBA (Confirmed).
What is Xvivo Perfusion AB (XVIPF) earnings time?
Xvivo Perfusion AB (XVIPF) earnings time is at Jan 27, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XVIPF EPS forecast?
XVIPF EPS forecast for the fiscal quarter 2025 (Q4) is 0.07.